CPNM estadio III: inmunoterapia

51 / 63

LCMC 3 Study: Neoadjuvant
Atezolizumab
Figure courtesy Rusch,
Rusch et al. ASCO
2018 Abstract 8541
- 4/19 (21%) pts
had MPR after
2 doses of
atezolizumab